Hospital Universitario de Salamanca, Salamanca, Spain
Eduardo Terán Brage Sr., Jorge Feito Pérez Sr., Roberto Andrés Escala Cornejo Sr., María Mar Abad Hernández , Sofía Del Carmen , Álvaro López Gutiérrez Sr., Belén Cigarral García , Rosario Vidal Tocino , Rebeca Lozano , Emilio Fonseca Sánchez Sr., Luis Miguel Navarro Martín Sr.
Background: Loss of MGMT expression has been suggested as a predictor of response to alkylating agents in pancreatic neuroendocrine tumors (pNET), however, its determination is controversial. We aim to analyze the prognostic value of MGMT status assessed by immunohistochemistry (IHC) or pyrosequencing (PSQ) in patients with pNET receiving CAPTEM. Methods: Retrospective and unicentric analysis in patients (p) with pNET treated with CAPTEM from April 2008 to February 2023. MGMTdeficiency was determined by IHC and MGMT promoter methylation by PSQ. We analyzed patients’ characteristics, progression-free survival (PFS) and overall survival (OS) according to MGMT status. Results: 20p were included. Age (median): 62 [46-77]. Males (45%). Tumor grade (G): G1 (15%), G2 (55%) and G3 (20%). MGMT deficiency was detected in 12p (60%) and promoter methylation in 10p (50%). Results by IHC were consistent with PSQ in 10p (50%), with mismatches in 4p (methylated MGMT and positive IHC) and 6p (unmethylated MGMT and negative IHC). We reported a higher response rate in MGMT-deficient and MGMT-methylated p (Table). In MGMT-deficient p we observed significantly better PFS (88m vs 11.1m; p=0.02, HR=0.21) and OS (141.9m vs 35.8m; p=0.03, HR=0.20). Also, in MGMT-methylated p we detected better PFS (88m vs 17.7m; p=0.20, HR=0.44) and OS (188.7m vs 141.9m; p=0.11, HR=0.28). A subanalysis was performed based on G, showing better PFS (88m vs 6.2m; p=0.03, HR=0.11) and OS (188.7m vs 35.8m; p<0.01, HR=0.06) in those with G2 vs G3. There was a strong negative correlation between G and MGMT by PSQ; the higher G, the lower probability of promoter methylation r(16)= -0.62, p<0.01. Conclusions: Our results support MGMT status, deficiency by IHC or promoter methylation by PSQ, as a potential prognostic biomarker in pNET treated with alkylating agents. However, it is necessary to evaluate its prognostic value in prospective studies.
MGMT (IHC) | MGMT (PSQ) | |||||
---|---|---|---|---|---|---|
1-2 (Low) | 3 (High) | Negative | Positive | |||
Response | Total | Total | ||||
Yes | 8 (66,7%) | 4 (50%) | 12 (60%) | 4 (40%) | 8 (80%) | 12 (60%) |
No | 4 (33,3%) | 4 (50%) | 8 (40%) | 6 (60%) | 2 (20%) | 8 (40%) |
Total | 12 (100%) | 8 (100%) | 20 (100%) | 10 (100%) | 10 (100%) | 20 (100%) |
OR [95% CI] of 2,0 [0,32-12,5] (p=0,64) | OR [95% CI] of 6,0 [0,81-44,31] (p=0,17) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Annual Meeting
First Author: Pamela L. Kunz
2022 ASCO Annual Meeting
First Author: Nick Pavlakis
2023 ASCO Annual Meeting
First Author: Paul James Mulholland
2022 ASCO Annual Meeting
First Author: Jennifer Rachel Eads